A master cancer gene hijacks a ‘molecular crowbar’ to make breast cancer cells invasive January 22, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
A master cancer gene hijacks a ‘molecular crowbar’ to make breast cancer cells invasive January 22, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
Breast Cancer First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer November 28, 2019 The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with…
Conferences Combination of immunotherapy and VEGF inhibitor improves survival in hepatocellular carcinoma November 28, 2019 Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall…